08:31 AM EST, 02/04/2025 (MT Newswires) -- Devonian Health Group ( DVHGF ) on Tuesday announced the results of its in-vitro study, comparing the anti-inflammatory effect of its lead candidate, Thykamine, to currently marketed anti-inflammatory agents.

When compared to the other agents, Thykamine showed clinically important and statistically significant higher inhibition potency for certain cytokines that induce inflammation, a statement reported.

"These results support the wide spectrum anti-inflammatory properties of Thykamine with potency that is superior to currently marketed anti-inflammatory agents. This study indicates a multi mode of action of Thykamine affecting several cytokines and other biomarkers, supporting the clinical efficacy demonstrated in phase 2 studies in ulcerative colitis and atopic dermatitis in adults," said Dr Louis Flamand, lead study investigator.

The assays were conducted at Laval University in Quebec.

Investigators of this study plan to submit the results in a peer-reviewed journal.